References
- Lu LG, Zeng MD, Mao YM, Li JQ, Wan MB, Li CZ, . (2003). Oxymatrine therapy for chronic hepatitis B: A randomized double-blind and placebo-controlled multi-center trial. World J Gastroenterol, 9:2480–3.
- Du S, Deng YJ, Liang W. (2006). Physicochemical properties study of oxymatrine. J Shenyang Pharmaceutical University, 23:80–3.
- Li ZW, Ma XY, Wang MN, Liang WW, Wang YH. (2004). Investigation of pharmacokinetics of oxymatrine soft capsule in healthy volunteers. Northwest. Pharm J, 19(4):149–51.
- Ellena JF, Le M, Cafiso D, Solis RM, Langston M, Sankaram MB. (1999). Distribution of phospholipids and triglycerides in multivesicular lipid particles. Drug Deliv, 6:97–106.
- Mantripragada S. (2002). A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog Lipid Res, 41:392–406.
- Grayson LS, Hansbrough JF, Zapata-Sirvent RL, Kim T, Kim S. (1993). Pharmacokinetics of DepoFoam gentamicin delivery system and effect on soft tissue infection. J Surg Res, 55:559–64.
- Huh J, Chen JC, Furman GM, Malki C, King B, Kafie F, . (1998). Local treatment of prosthetic vascular graft infection with multivesicular liposome-encapsulated amikacin. J Surg Res, 74:54–8.
- Jain SK, Jain RK, Chourasia MK, Jain AK, Chalasani KB, Soni V, . (2005). Design and development of multivesicular liposomal depot delivery system for controlled systemic delivery of acyclovir sodium. AAPS PharmSciTech, 6:E35–41.
- Langston MV, Ramprasad MP, Kararli TT, Galluppi GR, Katre NV. (2003). Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam). J Control Release, 89:87–99.
- Ramprasad MP, Amini A, Kararli T, Katre NV. (2003). The sustained granulopoietic effect of progenipoietin encapsulated in multivesicular liposomes. Int J Pharm, 261:93–103.
- Ramprasad MP, Anantharamaiah GM, Garber DW, Katre NV. (2002). Sustained-delivery of an apolipoprotein E-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels. J Control Release, 79:207–18.
- Zhong H, Deng Y, Wang X, Yang B. (2005). Multivesicular liposome formulation for the sustained delivery of breviscapine. Int J Pharm, 301:15–24.
- Van der Merwe SM, Verhoef JC, Verheijden JHM, Kotzé AF, Junginger HE. (2004). Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm, 58:225–35.
- Thanou M, Verhoef JC, Verheijden JHM, Junginger HE. (2001). Intestinal absorption of octreotide using trimethyl chitosan chloride: Studies in pigs. Pharm Res, 18:823–8.
- Sieval AB, Thanou M, Kotzé AF, Verhoef JC, Brussee J, Junginger HE. (1998). Preparation and NMR characterization of highly substituted N-trimethyl chitosan chloride. Carbohyd Polym, 36:157–65.
- Hamman JH, Kotze AF. (2001). Effect of the type of base and number of reaction steps on the degree of quaternization and molecular weight of N-trimethyl chitosan chloride. Drug Dev Ind Pharm, 27:373–80.
- Kim S, Turker MS, Chi EY, Sela S, Martin GM. (1983). Preparation of multivesicular liposomes. Biochim Biophys Acta, 728:339–48.
- Du S, Deng YJ. (2006). Studies on the encapsulation of oxymatrine into liposomes by ethanol injection and pH gradient method. Drug Dev Ind Pharm, 32:791–7.
- Polnok A, Borchard G, Berhoef JC, Sarisuta N, Junginger HE. (2004). Influence of methylation process on the degree of quaternization of N-trimethyl chitosan chloride. Eur J Pharm Biopharm, 57:77–83.
- Thanou M, Verhoef JC, Marbach P, Junginger HE. (2000). Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J Pharm Sci, 89:951–7.
- Thanou M, Verhoef JC, Junginger HE. (2001). Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev, 50:S91–101.
- Zheng QZ, Liu LJ, Bai XC. (2007). Preparation of oxymatrine liposomes and evaluation of the quality. China Pharm, 18:760–2.
- Gregoriadis G. (1993). Liposome techology. 2nd ed. London: CRC.
- Wang ML, Zhou QL, Wang BX. (2001). Studies on metabolism of oxymatrine by human intestinal bacteria. China J Chin Mater Med, 26:272.